Comparative Efficacy and Safety Study of CYB704 and Ocrelizumab in Relapsing Multiple Sclerosis Patients

The primary objective of this study is to evaluate the **efficacy** and **safety** of the proposed ocrelizumab biosimilar CYB704 in comparison to Ocrevus in participants with **relapsing multiple sclerosis**. This includes individuals with relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis. The clinical relevance of this objective lies in determining whether the biosimilar can provide a comparable therapeutic effect and safety profile to the established treatment, Ocrevus, thereby potentially offering an alternative treatment option for patients.

The clinical trial involves a total of **355 participants** diagnosed with **relapsing multiple sclerosis**, including both relapsing-remitting MS and active secondary progressive MS. The study population comprises both male and female subjects, with an age range that includes adults. Participants were selected based on specific criteria, although the principal inclusion criteria were not provided. The trial includes a vulnerable population, indicating that special considerations may be necessary for their participation. Lifestyle factors such as diet, physical activity, or habits were not specified in the available data. The sponsor did not provide detailed information regarding the general health status of the participants beyond their diagnosis of multiple sclerosis.

The clinical trial is designed to evaluate the **efficacy** and safety of a proposed ocrelizumab biosimilar, CYB704, compared to Ocrevus in participants with **relapsing multiple sclerosis**, including both relapsing-remitting MS and active secondary progressive MS. The trial is structured as a randomized, double-blind, controlled study, ensuring that neither the participants nor the investigators are aware of the treatment assignments, thus minimizing bias. The trial is set to commence recruitment on July 7, 2025, and is expected to conclude by May 30, 2029, providing a comprehensive assessment over a four-year period.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This initial visit will involve a thorough assessment of the participant's medical history and current health status. Following successful screening, participants will be randomized to receive either the biosimilar or the reference product. Throughout the trial, regular follow-up visits will be scheduled to monitor the participants' health, assess the **pharmacokinetics** and **pharmacodynamics** of the treatments, and evaluate any adverse events. These visits are crucial for ensuring participant safety and collecting data on the primary and secondary endpoints of the study.

The end-of-study visit will mark the completion of the participant's involvement in the trial, during which final assessments will be conducted to gather comprehensive data on the long-term effects of the treatment. The expected length of participant involvement will vary depending on the individual's response to treatment and adherence to the study protocol. Conditions that may lead to early termination from the study include significant adverse reactions, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is conducted in accordance with ethical guidelines and regulatory requirements, ensuring the integrity of the data collected and the safety of all participants involved.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the study may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments, including their names, dosages, or administration routes. The trial documentation does not specify any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized under phase 5, indicating a focus on post-marketing surveillance and long-term effects. The estimated recruitment start date is July 7, 2025, with an anticipated end date of May 30, 2029. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, the trial will likely involve systematic data collection and analysis to evaluate treatment outcomes. The methodology will adhere to standard clinical trial protocols, ensuring rigorous assessment of the intervention's effectiveness over the specified duration.